resistant hypertension
Conditions
Interventions
experimental group:pharmacogenomics testing
control group:Antihypertensive treatment under guidelines
Sponsors
Cardiovascular department of the First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Signed and dated ICF prior to any study-mandated procedure; 2. male and female 3. 18 years or older; 4. No other hypertension related clinical study; 5. Historical documentation in the subject's medical records on uncontrolled BP despite at least 3 background antihypertensive medications; Treated with at least 3 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit; Office based SBP >= 140mmHg and (or) DBP>= 90 mmHg; daytime mean blood pressure >= 135/85mmHg, or 24-hour blood pressure >= 130/80mmHg or night blood pressure >=120/70mmHg.
Exclusion criteria
Exclusion criteria: 1. Pseudo-RHT due to white clothing effect, medical inertness, treatment of poor compliance or secondary causes of hypertension (except sleep apnea). 2. Confirmed severe hypertension (level 3): SiSBP >= 180 mmHg and/or SiDBP >= 110 mmHg measured at two different points in time. 3. Pregnant or lactating woman. 4. Clinically significant unstable heart disease. 5. Severe renal insufficiency. 6. Any known factor, disease or clinically relevant medical or surgical condition that may put the subject at risk and affect treatment compliance, research conducted or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| systolic blood pressure of clinical room; | — |
Secondary
| Measure | Time frame |
|---|---|
| systolic blood pressure of clinincal room;24-hour mean blood pressure; | — |
Countries
China
Contacts
Public ContactZhao Li
The First Clinical College of the First Affiliated Hospital of China Medical University
Outcome results
None listed